Merk D - Search Results

1

Imig JD, Merk D, Proschak E. Imig JD, et al. Among authors: merk d. Kidney360. 2021 Aug 2;2(10):1645-1653. doi: 10.34067/KID.0003582021. eCollection 2021 Oct 28. Kidney360. 2021. PMID: 35372984 Free PMC article.

2

A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. Hye Khan MA, et al. Among authors: merk d. Biochem Pharmacol. 2019 Aug;166:212-221. doi: 10.1016/j.bcp.2019.05.023. Epub 2019 May 23. Biochem Pharmacol. 2019. PMID: 31129048 Free PMC article.

3

THE EFFECT OF COMPOUND DM509 ON KIDNEY FIBROSIS IN THE CONDITIONS OF THE EXPERIMENTAL MODEL.

Stavniichuk A, Savchuk O, Khan AH, Jankiewicz WK, Imig JD, Merk D. Stavniichuk A, et al. Among authors: merk d. Visnyk Kyivskoho Natsionalnoho Universytetu Imeni Tarasa Shevchenka Biolohiia. 2020;80(1):10-15. doi: 10.17721/1728_2748.2020.80.10-15. Visnyk Kyivskoho Natsionalnoho Universytetu Imeni Tarasa Shevchenka Biolohiia. 2020. PMID: 33437972 Free PMC article.

4

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).

Lamers C, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Expert Opin Ther Pat. 2012 Jul;22(7):803-41. doi: 10.1517/13543776.2012.699042. Epub 2012 Jun 15. Expert Opin Ther Pat. 2012. PMID: 22697317 Review.

5

Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.

Lamers C, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Curr Top Med Chem. 2014;14(19):2188-205. doi: 10.2174/1568026614666141112103516. Curr Top Med Chem. 2014. PMID: 25388533 Review.

6

Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.

Willems S, Zaienne D, Merk D. Willems S, et al. Among authors: merk d. J Med Chem. 2021 Jul 22;64(14):9592-9638. doi: 10.1021/acs.jmedchem.1c00186. Epub 2021 Jul 12. J Med Chem. 2021. PMID: 34251209 Review.

7

Automated design of multi-target ligands by generative deep learning.

Isigkeit L, Hörmann T, Schallmayer E, Scholz K, Lillich FF, Ehrler JHM, Hufnagel B, Büchner J, Marschner JA, Pabel J, Proschak E, Merk D. Isigkeit L, et al. Among authors: merk d. Nat Commun. 2024 Sep 11;15(1):7946. doi: 10.1038/s41467-024-52060-8. Nat Commun. 2024. PMID: 39261471 Free PMC article.

8

Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators.

Lamers C, Flesch D, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Expert Opin Ther Pat. 2013 Jan;23(1):47-77. doi: 10.1517/13543776.2013.736495. Epub 2012 Nov 14. Expert Opin Ther Pat. 2013. PMID: 23151189 Review.

9

Natural compound renews hope for diabetes and obesity therapeutic target.

Merk D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2015;7(7):833-5. doi: 10.4155/fmc.15.40. Future Med Chem. 2015. PMID: 26061101 No abstract available.

10

N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.

Blöcher R, Lamers C, Wittmann SK, Merk D, Hartmann M, Weizel L, Diehl O, Brüggerhoff A, Boß M, Kaiser A, Schader T, Göbel T, Grundmann M, Angioni C, Heering J, Geisslinger G, Wurglics M, Kostenis E, Brüne B, Steinhilber D, Schubert-Zsilavecz M, Kahnt AS, Proschak E. Blöcher R, et al. Among authors: merk d. J Med Chem. 2016 Jan 14;59(1):61-81. doi: 10.1021/acs.jmedchem.5b01239. Epub 2015 Dec 25. J Med Chem. 2016. PMID: 26595749

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page